Cubist completes Trius acquisition
LEXINGTON, Mass. — Cubist has completed its purchase of Trius Therapeutics, Cubist said.
The $704 million acquisition will give Cubist control of the drug tedizolid phosphate, an experimental drug that it said had the potential to treat resistant infections. Trius ceased to be traded on the NASDAQ earlier this week.
"The need for new treatments to combat drug-resistant bacteria is growing, and we will work diligently to bring this antibiotic product candidate to market in order to help hospitals and their patients combat these infections," Cubist CEO Michael Bonney said. "This transaction is also an important step toward achieving Cubist’s ‘Building Blocks of Growth’ and continuing our track record of driving shareholder value over the long term."
UnitedHealthcare sponsors Medicare Education Week
MINNETONKA, Minn. — Health insurer UnitedHealthcare is sponsoring a weeklong education program for Medicare patients, the company said Friday.
Starting Sunday, one month before Medicare’s annual open-enrollment period, UnitedHealthcare’s National Medicare Education Week is designed to help baby boomers, existing beneficiaries, their families and caregivers learn more about Medicare. The open-enrollment period lasts from Oct. 15 to Dec. 7.
"Dispelling Medicare confusion is important because healthcare decisions can have a significant impact on the well-being and wallets of seniors and other Medicare beneficiaries," UnitedHealthcare Medicare & Retirement CEO Jack Larsen said. "Medicare is not a one-size-fits-all program, and making coverage choices requires thoughtful planning."
According to the company, baby boomers in their early 60s who are approaching eligibility for Medicare have struggled to understand the program, with 70% describing their understanding of it as "fair" or "poor," and more than half saying they wouldn’t "know where to begin" when it comes to preparing for the transition from employer-sponsored insurance to Medicare.
ChapStick introduces new Hydration Lock for healthier, nourished lips
Madison, N.J. — ChapStick, part of the Pfizer portfolio of consumer brands, on Friday announced a new lip balm with advanced moisturizing and anti-aging ingredients.
ChapStick Hydration Lock has a clinically proven formula that works by locking in the natural moisture of lips while also drawing in moisture from the outside helping to keep lips hydrated for a full eight hours. According to the company, Hydration Lock gives lips a fuller, smoother appearance, provides instant smoothness and reflects light from the lips that reduces the appearance of wrinkles and fine lines.
ChapStick Hydration Lock contains a nourishing and revitalizing complex of ingredients, the company stated, including antioxidants CoQ10 and vitamin E, both of which help resist environmental oxidative damage to lips; ultra-hydrating Hyaluronic Spheres, which support soft, supple, fuller lips; and natural botanical extract, which is known to revitalize skin.
ChapStick Hydration Lock is available in vanilla crème flavor at stores nationwide for a suggested retail price of $2.49 to $2.99.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.